Plexxikon, Roche File Rx/Dx Application for PLX4032, Cobas Mutation Test in Metastatic Melanoma
May 18, 2011
Plexxikon, Roche File Rx/Dx Application for PLX4032, Cobas Mutation Test in Metastatic Melanoma
Plexxikon is seeking marketing approval for PLX4032 for the treatment of metastatic melanoma in patients harboring the BRAF V600 mutation. Simultaneously, Roche Molecular Diagnostics has submitted a premarket approval application to the FDA for its Cobas 4800 BRAF V600 Mutation Test.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- FDA Simultaneously Approves Roche/Plexxikon's Drug, Companion Dx for BRAF-Mutated Melanoma
August 17, 2011 / Pharmacogenomics Reporter - Roche Says FDA-Approved BRAF Test Is Better Than Sanger-based LDTs, but is it Enough to Sway Labs?
September 28, 2011 / Pharmacogenomics Reporter - NEJM Paper Yields Positive Efficacy Results for Roche/Plexxikon's PGx Melanoma Drug
September 1, 2010 / Pharmacogenomics Reporter - Roche Offers Rx/Dx Pipeline Update at UBS Life Sciences Conference
September 23, 2009 / Pharmacogenomics Reporter - UK's NICE Cites Lack of Response Markers for BMS' Yervoy as Factor in Negative Recommendation
October 19, 2011 / Pharmacogenomics Reporter